Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H14BrN3O3 |
| Molecular Weight | 376.205 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C2C(NC3=CC(Br)=C(O)C=C3)=NC=NC2=C1
InChI
InChIKey=CBIAKDAYHRWZCU-UHFFFAOYSA-N
InChI=1S/C16H14BrN3O3/c1-22-14-6-10-12(7-15(14)23-2)18-8-19-16(10)20-9-3-4-13(21)11(17)5-9/h3-8,21H,1-2H3,(H,18,19,20)
| Molecular Formula | C16H14BrN3O3 |
| Molecular Weight | 376.205 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9796979 | https://www.ncbi.nlm.nih.gov/pubmed/27119652
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9796979 | https://www.ncbi.nlm.nih.gov/pubmed/27119652
WHI-P154 is an inhibitor of Janus-activated kinase JAK3. Also this drug inhibits other common kinases including EGFR, Src, Abl, VEGFR and others. WHI-P154 is potent inhibitor of glioblastoma cell adhesion and migration. Further preclinical development of WHI-P154 may provide the basis for the design of more effective adjuvant chemotherapy programs for glioblastoma multiforme. Treatment of ALK inhibitor, WHI-P154 resulted in the down-regulation of aberrant anaplastic lymphoma kinase (ALK) signaling, shrinkage of tumor, and suppression of metastasis and significantly improved survival of ALK mutant-bearing mice.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.8 µM [IC50] | |||
Target ID: CHEMBL203 |
4.0 nM [IC50] | ||
Target ID: CHEMBL1862 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1868 |
|||
Target ID: CHEMBL4247 |
26.9 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. | 1998 Jun |
|
| The specificity of JAK3 kinase inhibitors. | 2008 Feb 15 |
|
| Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha. | 2008 Jan |
|
| Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway. | 2010 Oct |
Patents
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:57:11 UTC 2023
by
admin
on
Sat Dec 16 11:57:11 UTC 2023
|
| Record UNII |
PG8BT6T9MB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PG8BT6T9MB
Created by
admin on Sat Dec 16 11:57:11 UTC 2023 , Edited by admin on Sat Dec 16 11:57:11 UTC 2023
|
PRIMARY | |||
|
3795
Created by
admin on Sat Dec 16 11:57:11 UTC 2023 , Edited by admin on Sat Dec 16 11:57:11 UTC 2023
|
PRIMARY | |||
|
DTXSID60274407
Created by
admin on Sat Dec 16 11:57:11 UTC 2023 , Edited by admin on Sat Dec 16 11:57:11 UTC 2023
|
PRIMARY | |||
|
211555-04-3
Created by
admin on Sat Dec 16 11:57:11 UTC 2023 , Edited by admin on Sat Dec 16 11:57:11 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR | |||
|
|
TARGET -> INHIBITOR | |||
|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR | |||
|
|
TARGET -> INHIBITOR | |||
|
|
TARGET -> INHIBITOR |
IC50
|
